Introduction
Prolongation of the QTc interval on electrocardiogram (ECG) is associated with an increased risk of ventricular arrhythmias and sudden cardiac death. 1 QTc prolongation results from dysfunction of cardiac ion channels; predominantly altered function of cardiac potassium (I kr and I ks ) or cardiac sodium channels (I na ) may elicit the phenotype of the long QT syndrome. 2 In the congenital form of long
Learning points
• Patients with a KCNE1 D85N variant should avoid reversible risk factors for drug-induced long QT syndrome (diLQTS).
• The finding of a KCNE1 D85N variant can be used to determine whether the relatives share the same increased risk of diLQTS.
. QT syndrome (cLQTS), the ion channels are dysfunctional due to inherited mutations 2 but the same ion channels can also be affected by numerous drugs and hypokalaemia. 3 Drug-induced long QT syndrome (diLQTS) is mainly caused by drugs affecting the promiscuous hERG channel. 4 However, recent studies have also identified an additional underlying genetic disposition or susceptibility to diLQTS; 30% carry a mutation in the KCNQ1, KCNH2, SCN5A, KCNE1, or KCNE2 genes. 5 These patients can be perceived as having as a subclinical form of cLQTS, which will only be expressed when the I kr current is exposed to a blocking agent. The identification of a disease-causing or a susceptibility inducing mutation may be useful in counselling the proband and relatives at possible risk.
Timeline Case presentation
A 54-year-old woman was brought to the emergency department after a syncope at home. The patient had been cleaning the barbecue in the garden when she felt 'hard heart beats' and passed out without further warning. The patient had no memory of the incident that had resulted in a mild head trauma. Her past medical history was remarkable for deep vein thrombosis (10 years earlier), ankylosing spondylitis, depression, and a recent transient ischaemic attack (TIA). Approximately 5 years earlier the patient had undergone a coronary angiogram following an episode of chest pains. The angiogram had identified no atheromatosis. Cardiovascular risk factors encompassed hypertension, wellcontrolled hypercholesterolaemia, and depression. The patient had never smoked and did not have diabetes or a family history of heart disease or sudden premature death. The physical examination, including a cardiac and neurological examination, showed no abnormalities.
At admission, the patient was prescribed the following: citalopram 40 mg/day, adalimumab 40 mg subcutaneously/2 weeks (for ankylosing spondylitis), paracetamol p.n. 1 g max 4 times/day, enalapril 10 mg/day, atorvastatin 40 mg/day, and clopidogrel 75 mg/day.
A CT scan of the cerebrum showed no cerebral damage. The ECG showed sinus rhythm and QTc interval þ600 ms ( Figure 1A After 1 day of telemetry, an episode of self-terminating Torsade de Pointes (TdP) lasting 18 s was recorded ( Figure 1B ). The patient was conscious during the episode but reported feeling dizzy and that symptoms were similar to what she had felt before her syncope the previous day. Empirical treatment with 16 mmol intravenous magnesium and 3 g of potassium chloride was immediately given. Serum potassium increased to 3.8 mmol/L on the following day but the QTc interval remained prolonged (640 ms).
The case was conferred with a psychiatrist, and citalopram was tapered under simultaneous rapid titration of sertraline to 100 mg/ day. Citalopram was completely discontinued from Day 5. At 1 week from admission, the QTc duration was within normal range ( Figure  1C , QTc 450 ms), but the QTc duration fluctuated and was found outside normal range at Day 9 (600 ms), before normalization at Day 15 (460 ms). Earlier ECGs were available for evaluation; previous recordings showed QTc between 440 and 580 ms ( Figure 1D) .
At this point, it was considered possible that the patient was afflicted with the congenital long QT syndrome; even though two known triggers of induced QTc prolongation were present, correction of these did not clearly normalize QTc duration. In addition, previous ECG recordings clearly documented intermittent, significant QTc prolongation over an extended time period. On Day 8 treatment with atenolol 25 mg was initialized. On Day 9, an implantable cardioverter-defibrillator (VVI-ICD) was implanted. Genetic testing was ordered and the proband was found to be heterozygote carrier of the KCNE1 D85N (c.253G>A) variant.
The patient was closely followed the first 6 months after the TdP episode and seen monthly in the out-patient clinic. Currently, the patient is scheduled for follow-up with her cardiologist yearly, her ICD is interrogated in clinic every 6 months and by remote monitoring every 4 months. In 18 months of follow-up, the ICD has not registered any arrhythmias.
Discussion
We present a patient with syncope, severe QTc prolongation, and variant has been associated with an increase in QTc interval of 8 ms. 6 Also, the variant is over-represented in patients with diLQTS 7 and is a known modifier gene in cLQTS, type one. 8 Distinguishing between diLQTS and cLQTS is challenging as there is a significant overlap in the phenotype including QTc duration on the ECG. 5 One study reported that 40% of patients with diLQTS may have an underlying cLQTS diagnosis. 9 When applying the cLQTS score on our patient, she would receive three points in total (two points for TdP and one for syncope). Three points would categorize the patients as having 'intermediate probability of cLQTS'. 1 However, due to the reversible QT-prolongation, which normalized after discontinuing citalopram and correction of mild hypokalaemia, she was considered to have diLQTS.
Citalopram has a half-life of 36 h, and the patient's QTc interval was within normal range 4 days (Day 7) after substitution of citalopram with sertraline. Also, we found that on Day 9, the QTc interval was prolonged to 600 ms, which suggests that the QT-prolongation observed on the ECGs from this patient was not solely explained by treatment with citalopram. Consequently, we advised the patient to avoid all QTc prolonging drugs in the future. According to 2015 ESC guidelines, implantation of an ICD in cases with drug-related pro-arrhythmia, should rely on an individual evaluation (Class IIa, Level C). 10 Based on the serial ECG findings in our patient, we remained unassured that her risk of future malignant arrhythmias would be sufficiently controlled solely by avoiding QTc prolonging drugs, therefore, an ICD was implanted. This is supported by the only recent study with long-term follow-up on diLQTS patients with ICDs, where they reported that 44% of patients with an ICD following aborted sudden cardiac death due to diLQTS received appropriate shocks during a mean follow-up of 84 ± 55 months. 11 In contrast, among patients with cLQTS, only 18-28% of patients with cLQTS experience appropriate shocks by their ICD. 12, 13 Though device programming may differ between studies and account for some of this observed difference, one may speculate that we at this point only identify the most malignant subgroup of diLQTS patients since their subsequent risk of ICD shocks is relatively high. Different drug classes can cause diLQTS and TdP; a frequently updated online tool is available for risk assessment by drug type for physicians and patients.
14 Citalopram is listed in the category of highest risk ('Known Risk of TdP'). Moreover, a Danish study associated citalopram with a 30% increase in risk for out-of-hospital cardiac arrest. 15 This data supported our concern that citalopram may have elicited the arrhythmias observed in this patient. The genetic test result supported the notion that the patient was at increased risk of druginduced ECG alterations and hereby at risk of malignant arrhythmias. However, it should be noted that the minor allele frequency of KCNE1 D85N (c.253G>A) occurs with an approximate 1.3% percent frequency in the Danish background population. Also, the patient had several other risk factors for diLQTS: female sex, age, pre-citalopram QTc interval in the high-normal range, and a slightly reduced potassium level. The individual contribution of these distinct risk factors is probably impossible to estimate in the clinical setting. At this point genetic testing and counselling should be tailored to the individual. In this family, one could interpret the findings as the proband as carrying a genetic susceptibility to drug-induced arrhythmias and screen family members accordingly (Figure 2 ).
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